Detailed results from the phase 3 TEMPO trials show tavapadon offers a mechanistically distinct approach for managing motor ...
Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an ...
Adults with type 1 diabetes had an increase in total daily insulin dose and bolus insulin dose shortly after stopping ...
A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can ...
Current GLP-1 standards of care focus on once-weekly dosing, with doctor-recommended, supervised titration depending on ...
Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
Falls and other non-dopaminergic symptoms in Parkinson’s disease remain a significant unmet need, with limited effective ...
In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.
A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results